Categories Earnings, Technology

Zscaler’s Q2 results beat market estimates

Zscaler Inc. (NASDAQ: ZS) beat revenue and earnings estimates for the second quarter of 2020 but the outlook fell below estimates, causing the stock to crash by more than 10% in aftermarket hours on Thursday.

The cloud security company reported a 36% year-over-year increase in total revenue to $101.3 million, beating forecasts of $98.9 million.  

GAAP net loss was $29.2 million, or $0.23 per share, compared to $3.6 million, or $0.03 per share, in the prior-year period. Adjusted net income totaled $12 million, or $0.09 per share, surpassing projections of $0.03 per share.

Zscaler Q2 2020 revenue and earnings trend

Calculated billings grew 18% to $135.4 million and deferred revenue increased 36% to $280 million compared to last year.

For the third quarter of 2020, the company expects total revenue of $105-107 million and adjusted EPS of approx. $0.01-0.03. This fell short of Wall Street’s estimates of $0.04 per share for the third quarter.

For the full year of 2020, revenue is expected to be $414-417 million and adjusted EPS is expected to be $0.14-0.16. Calculated billings is estimated to range between $512-517 million.

Zscaler has been strengthening its product portfolio to keep pace with industry leaders like Cisco (CSCO) while giving competition to peers. As a result, the company continues to expand its user-base. More and more businesses, including top-tier companies, are adopting Zscaler’s cloud security solutions.

According to Allied Market Research, the global cloud security market is expected to grow to $8.9 billion by 2020, reflecting a CAGR of 23.5% during the period from 2015-2020.  

Last month, Zscaler reached an agreement with Broadcom (NASDAQ: AVGO), resulting in the dismissal of all patent lawsuits filed against Zscaler by Symantec, which was acquired by Broadcom. As part of the settlement, Zscaler agreed to pay $15 million to Broadcom.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top